-10.0%



-10.8%













FY2025 Outlook





Updating Full Year Management Guidance, and Reported and Core Forecasts





Takeda has updated its full year outlook to reflect foreign exchange impacts and impairment charges related to the cell therapy platform.







FY2025 Management Guidance Core Change at CER (Non-IFRS)







FY2025 ORIGINAL MANAGEMENT GUIDANCE
(May 2025)



FY2025 REVISED MANAGEMENT GUIDANCE
(October 2025)





Core Revenue



Broadly flat



=*=*=*=*=*=
当前为第7/19页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页